Effect of Unani formulations in Kidney Disease
Phase 2
- Conditions
- Health Condition 1: N181- Chronic kidney disease, stage 1Health Condition 2: N182- Chronic kidney disease, stage 2 (mild)Health Condition 3: N183- Chronic kidney disease, stage 3 (moderate)
- Registration Number
- CTRI/2022/04/041565
- Lead Sponsor
- ational Institute of Unani Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1.Diagnosed cases of CKD stage 1 to 3b associated with or without hypertension and/or diabetes mellitus on treatment
2.eGFR >=30- <=90 ml/min/1.73 m2 (CKD-EPI 2009)
3.Sr. creatinine level >= 1.1- <= 6 mg/dL (Jaffe method)
4.Patients who will give consent and able to do follow up
Exclusion Criteria
1.Urine albumin > 2+ ( > 300 mg/L) (Reagent strip urinalysis)
2.Patient with BP >140/90 mm Hg while taking 4 or more anti-hypertensive agents
3.Patients with HbA1c > 8%
4.Presence of urinary red cell casts, RBC > 20/hpf
5.H/O recurrent or extensive nephrolithiasis
6.Hereditary kidney disease
7.Severe systemic illness
8.Pregnant and lactating women
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method